Home LiteratureArticle Details
PMID: 18395015 Published · ppublish English Journal Article Review

Oxidative and nitrative protein modifications in Parkinson's disease.

Free radical biology & medicine ·Vol. 44 ·No. 10 ·2008-05-15 ·Pages 1787-94

Danielson SR, Andersen JK

Abstract

Parkinson's disease (PD) is a complex neurodegenerative syndrome likely involving contributions from various factors in individuals including genetic susceptibility, exposure to environmental toxins, and the aging process itself. Increased oxidative stress appears to be a common causative aspect involved in the preferential loss of dopaminergic neurons in a region of the brain prominently affected by the disorder, the substantia nigra (SN). Loss of dopaminergic SN neurons is responsible for the classic clinical motor symptoms associated with PD. Several oxidative and nitrative posttranslational modifications (PTMs) have been identified on proteins pertinent to PD that may affect this or other aspects of disease progression. In this review, we discuss several examples of such PTMs to illustrate their potential consequences in terms of initiation or progression of PD neuropathophysiology.

MeSH Terms
Brain/metabolism,pathology Dopamine/metabolism Humans Neurons/metabolism,pathology Nitric Oxide/metabolism Oxidation-Reduction Oxidative Stress Parkinson Disease/metabolism Protein Processing, Post-Translational
Chemicals
Nitric Oxide Dopamine
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Danielson Steven R
Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA.
Andersen Julie K
References (103)
103 references, click to expand
  1. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease.
    J Biol Chem. 2000 Aug 25;275(34):26096-101 PMID: 10846169
  2. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease.
    J Neurochem. 1997 Sep;69(3):1326-9 PMID: 9282961
  3. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.
    Am J Pathol. 1998 Apr;152(4):879-84 PMID: 9546347
  4. 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. Identification of proteasomes as target molecules.
    J Biol Chem. 1999 Aug 20;274(34):23787-93 PMID: 10446139
  5. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.
    Science. 1997 Jun 27;276(5321):2045-7 PMID: 9197268
  6. alpha-Synuclein is phosphorylated in synucleinopathy lesions.
    Nat Cell Biol. 2002 Feb;4(2):160-4 PMID: 11813001
  7. Modification of Parkinsonism--chronic treatment with L-dopa.
    N Engl J Med. 1969 Feb 13;280(7):337-45 PMID: 4178641
  8. Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells.
    Biochem Biophys Res Commun. 2004 May 7;317(3):722-8 PMID: 15081400
  9. Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    J Neurochem. 2001 Jan;76(2):637-40 PMID: 11208927
  10. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism.
    Science. 2003 Jan 10;299(5604):256-9 PMID: 12446870
  11. Oxidative stress and nitration in neurodegeneration: cause, effect, or association?
    J Clin Invest. 2003 Jan;111(2):163-9 PMID: 12531868
  12. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.
    Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2696-701 PMID: 8610103
  13. Effect of proteasome inhibition on cellular oxidative damage, antioxidant defences and nitric oxide production.
    J Neurochem. 2001 Jul;78(1):32-41 PMID: 11432971
  14. The proteasomal system and HNE-modified proteins.
    Mol Aspects Med. 2003 Aug-Oct;24(4-5):195-204 PMID: 12892997
  15. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease.
    J Neurochem. 1989 Feb;52(2):381-9 PMID: 2911023
  16. Nitration and inactivation of tyrosine hydroxylase by peroxynitrite.
    J Biol Chem. 2001 Dec 7;276(49):46017-23 PMID: 11590168
  17. INFLUENCE OF THE SUBSTANTIA NIGRA ON THE CATECHOLAMINE CONTENT OF THE STRIATUM.
    Brain. 1965 Mar;88:181-92 PMID: 14280273
  18. Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome.
    J Biol Chem. 2002 Aug 9;277(32):28572-7 PMID: 12034719
  19. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function.
    Science. 2004 May 28;304(5675):1328-31 PMID: 15105460
  20. Cellular oligomerization of alpha-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence.
    J Biol Chem. 2007 Oct 26;282(43):31621-30 PMID: 17785456
  21. The biochemistry of Parkinson's disease.
    Annu Rev Biochem. 2005;74:29-52 PMID: 15952880
  22. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1.
    PLoS Biol. 2007 Jul;5(7):e172 PMID: 17579517
  23. Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition.
    Biochem Biophys Res Commun. 2003 Dec 26;312(4):1342-8 PMID: 14652021
  24. Genetics of Parkinson disease: paradigm shifts and future prospects.
    Nat Rev Genet. 2006 Apr;7(4):306-18 PMID: 16543934
  25. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase.
    Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14807-12 PMID: 17766438
  26. Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies.
    J Biol Chem. 2000 Jun 16;275(24):18344-9 PMID: 10747881
  27. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein.
    J Biol Chem. 2002 Jan 18;277(3):1641-4 PMID: 11707429
  28. Degradation of alpha-synuclein by proteasome.
    J Biol Chem. 1999 Nov 26;274(48):33855-8 PMID: 10567343
  29. Roles of distinct cysteine residues in S-nitrosylation and dimerization of DJ-1.
    Biochem Biophys Res Commun. 2006 Jan 13;339(2):667-72 PMID: 16316629
  30. Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o'-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease.
    J Biol Chem. 1999 Dec 3;274(49):34621-8 PMID: 10574926
  31. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species.
    J Neurochem. 1998 Nov;71(5):2112-22 PMID: 9798937
  32. Glutaredoxin 2 catalyzes the reversible oxidation and glutathionylation of mitochondrial membrane thiol proteins: implications for mitochondrial redox regulation and antioxidant DEFENSE.
    J Biol Chem. 2004 Nov 12;279(46):47939-51 PMID: 15347644
  33. Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6.
    Neurobiol Dis. 2007 Feb;25(2):401-11 PMID: 17141510
  34. Protein nitration in cardiovascular diseases.
    Pharmacol Rev. 2002 Dec;54(4):619-34 PMID: 12429871
  35. 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles.
    Biochem Biophys Res Commun. 1990 Aug 16;170(3):1049-55 PMID: 2167668
  36. Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity.
    Neurosci Lett. 1985 Dec 18;62(3):389-94 PMID: 3912685
  37. Early alpha-synuclein lipoxidation in neocortex in Lewy body diseases.
    Neurobiol Aging. 2008 Mar;29(3):408-17 PMID: 17166629
  38. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity.
    J Neurosci. 2000 Aug 15;20(16):6048-54 PMID: 10934254
  39. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization.
    Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9103-8 PMID: 15181200
  40. Protein nitration in Parkinson's disease.
    J Neuropathol Exp Neurol. 1998 Apr;57(4):338-42 PMID: 9600227
  41. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice.
    J Biol Chem. 2004 Apr 30;279(18):18614-22 PMID: 14985362
  42. Diagnosis and treatment of Parkinson disease: molecules to medicine.
    J Clin Invest. 2006 Jul;116(7):1744-54 PMID: 16823471
  43. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease.
    J Neurochem. 1989 Jun;52(6):1830-6 PMID: 2723638
  44. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions.
    Science. 2000 Nov 3;290(5493):985-9 PMID: 11062131
  45. The brain-stem lesions in Parkinsonism.
    J Neurol Neurosurg Psychiatry. 1953 Nov;16(4):213-26 PMID: 13109537
  46. Mitochondrial complex I deficiency in Parkinson's disease.
    Lancet. 1989 Jun 3;1(8649):1269 PMID: 2566813
  47. Mechanism of toxicity in rotenone models of Parkinson's disease.
    J Neurosci. 2003 Nov 26;23(34):10756-64 PMID: 14645467
  48. Tyrosine 125 of alpha-synuclein plays a critical role for dimerization following nitrative stress.
    Brain Res. 2002 May 31;938(1-2):73-80 PMID: 12031537
  49. Brain mitochondria catalyze the oxidation of 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxyli c acid (DHBT-1) to intermediates that irreversibly inhibit complex I and scavenge glutathione: potential relevance to the pathogenesis of Parkinson's disease.
    J Neurochem. 1998 Nov;71(5):2049-62 PMID: 9798930
  50. 6-Hydroxydopamine, a new oxidation mechanism.
    Eur J Pharmacol. 1972 Feb;17(2):287-92 PMID: 4337349
  51. Oxidative damage to mitochondrial complex I due to peroxynitrite: identification of reactive tyrosines by mass spectrometry.
    J Biol Chem. 2003 Sep 26;278(39):37223-30 PMID: 12857734
  52. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].
    Klin Wochenschr. 1960 Dec 15;38:1236-9 PMID: 13726012
  53. Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations.
    J Biol Chem. 2005 Jun 3;280(22):21212-9 PMID: 15817478
  54. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy.
    J Clin Invest. 2008 Feb;118(2):777-88 PMID: 18172548
  55. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies.
    Am J Pathol. 2000 Nov;157(5):1439-45 PMID: 11073803
  56. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled.
    J Neurosci. 2006 May 10;26(19):5256-64 PMID: 16687518
  57. Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons.
    PLoS One. 2008 Jan 02;3(1):e1376 PMID: 18167537
  58. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay.
    J Neurochem. 1998 Jan;70(1):268-75 PMID: 9422371
  59. Inhibition of the multicatalytic proteinase (proteasome) by 4-hydroxy-2-nonenal cross-linked protein.
    FEBS Lett. 1997 Mar 17;405(1):21-5 PMID: 9094417
  60. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria.
    Biochem J. 1980 Nov 1;191(2):421-7 PMID: 6263247
  61. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.
    Science. 2001 Nov 9;294(5545):1346-9 PMID: 11701929
  62. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains.
    J Neurochem. 1991 Mar;56(3):978-82 PMID: 1704426
  63. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors.
    J Biol Chem. 2002 Feb 15;277(7):5411-7 PMID: 11724769
  64. Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration.
    J Neurosci. 2007 Dec 19;27(51):13997-4006 PMID: 18094238
  65. Methionine sulfoxide reductase A and a dietary supplement S-methyl-L-cysteine prevent Parkinson's-like symptoms.
    J Neurosci. 2007 Nov 21;27(47):12808-16 PMID: 18032652
  66. Reversible glutathionylation of complex I increases mitochondrial superoxide formation.
    J Biol Chem. 2003 May 30;278(22):19603-10 PMID: 12649289
  67. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7659-63 PMID: 9636206
  68. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism.
    Nature. 1998 Apr 9;392(6676):605-8 PMID: 9560156
  69. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients.
    Neurosci Lett. 1986 Jun 30;67(3):269-74 PMID: 3737015
  70. Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation.
    J Biol Chem. 2004 Nov 12;279(46):47746-53 PMID: 15364911
  71. Cytotoxic and genotoxic potential of dopamine.
    J Neurosci Res. 1999 Mar 15;55(6):659-65 PMID: 10220107
  72. Specific cleavage of DJ-1 under an oxidative condition.
    Neurosci Lett. 2006 Oct 9;406(3):165-8 PMID: 16935423
  73. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.
    J Neurosci. 2002 Mar 1;22(5):1763-71 PMID: 11880505
  74. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease.
    Acta Neurol Scand Suppl. 1993;146:6-13 PMID: 8333254
  75. Parkinson's disease: a disorder due to nigral glutathione deficiency?
    Neurosci Lett. 1982 Dec 13;33(3):305-10 PMID: 7162692
  76. Up-regulation of gamma-glutamyl transpeptidase activity following glutathione depletion has a compensatory rather than an inhibitory effect on mitochondrial complex I activity: implications for Parkinson's disease.
    Free Radic Biol Med. 2006 May 1;40(9):1557-63 PMID: 16632116
  77. Antioxidants protect PINK1-dependent dopaminergic neurons in Drosophila.
    Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13520-5 PMID: 16938835
  78. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons.
    Nat Med. 1996 Sep;2(9):1017-21 PMID: 8782460
  79. Distinct mechanisms of neurodegeneration induced by chronic complex I inhibition in dopaminergic and non-dopaminergic cells.
    J Biol Chem. 2004 Dec 10;279(50):51783-92 PMID: 15469939
  80. S-thiolation of tyrosine hydroxylase by reactive nitrogen species in the presence of cysteine or glutathione.
    Antioxid Redox Signal. 2005 Jul-Aug;7(7-8):863-9 PMID: 15998241
  81. Iron dysregulation and Parkinson's disease.
    J Alzheimers Dis. 2004 Dec;6(6 Suppl):S47-52 PMID: 15665414
  82. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease.
    Brain. 2004 Feb;127(Pt 2):420-30 PMID: 14662519
  83. Dopamine covalently modifies and functionally inactivates parkin.
    Nat Med. 2005 Nov;11(11):1214-21 PMID: 16227987
  84. Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO-mediated pathway not involving peroxynitrite: implications for Parkinson's disease.
    J Neurochem. 2005 Mar;92(5):1091-103 PMID: 15715660
  85. Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells.
    J Neurosci. 2005 Jun 8;25(23):5544-52 PMID: 15944382
  86. Oxidized forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to sublethal levels of paraquat.
    Free Radic Res. 2001 Sep;35(3):301-10 PMID: 11697128
  87. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group.
    Ann Neurol. 1992;32 Suppl:S82-7 PMID: 1510385
  88. Mutational analysis of DJ-1 in Drosophila implicates functional inactivation by oxidative damage and aging.
    Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12517-22 PMID: 16894167
  89. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases.
    J Biol Chem. 2006 Apr 21;281(16):10816-24 PMID: 16517609
  90. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons.
    Am J Pathol. 1999 May;154(5):1423-9 PMID: 10329595
  91. Glutathione depletion in a midbrain-derived immortalized dopaminergic cell line results in limited tyrosine nitration of mitochondrial complex I subunits: implications for Parkinson's disease.
    Antioxid Redox Signal. 2005 Jul-Aug;7(7-8):900-10 PMID: 15998245
  92. Identification of rotenone-induced modifications in alpha-synuclein using affinity pull-down and tandem mass spectrometry.
    Anal Chem. 2006 Apr 1;78(7):2422-31 PMID: 16579629
  93. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease.
    J Neural Transm (Vienna). 1997;104(6-7):661-77 PMID: 9444566
  94. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
    Life Sci. 1985 Jul 1;36(26):2503-8 PMID: 2861548
  95. Peroxynitrite-induced nitration of tyrosine hydroxylase: identification of tyrosines 423, 428, and 432 as sites of modification by matrix-assisted laser desorption ionization time-of-flight mass spectrometry and tyrosine-scanning mutagenesis.
    J Biol Chem. 2002 Apr 19;277(16):14336-42 PMID: 11834745
  96. Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase.
    Brain Res. 1999 Mar 27;823(1-2):177-82 PMID: 10095024
  97. Hypothesis: proteasomal dysfunction: a primary event in neurogeneration that leads to nitrative and oxidative stress and subsequent cell death.
    Ann N Y Acad Sci. 2002 May;962:182-94 PMID: 12076974
  98. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra.
    J Neurochem. 1997 Sep;69(3):1196-203 PMID: 9282943
  99. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?
    Acta Neurol Scand Suppl. 1989;126:47-54 PMID: 2618593
  100. Induction of alpha-synuclein aggregation by intracellular nitrative insult.
    J Neurosci. 2001 Oct 15;21(20):8053-61 PMID: 11588178
  101. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease.
    Nat Med. 1999 Dec;5(12):1403-9 PMID: 10581083
  102. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.
    J Biol Chem. 2006 Oct 6;281(40):29739-52 PMID: 16847063
  103. 5-s-Cysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons.
    J Neurochem. 2002 Apr;81(1):122-9 PMID: 12067224
Article Info
Journal
Free radical biology & medicine
Abbr.
Free Radic Biol Med
ISSN
0891-5849
DOI
10.1016/j.freeradbiomed.2008.03.005
Published
2008-05-15
Epub
2008-00-18
Pages
1787-94
Language
English
Region
United States
NLM ID
8709159
PMCID
PMC2422863
Subset
IM
Grants
NINDS NIH HHS · RL1 NS062415 · United States
NINDS NIH HHS · RL1 NS062415-01 · United States
External Links
PubMed source DOI: 10.1016/j.freeradbiomed.2008.03.005 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2